Building a database for severe ADAMTS13 deficiency
Part of Blood & lymphatic clinical trials.
This trial is creating a research database for people with severe ADAMTS13 deficiency, a condition where the body has very low activity of a key blood-protein. It may help researchers better understand the condition by collecting and organizing patient information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with severe ADAMTS13 deficiency (ADAMTS13 activity under 10%), based on your medical records or screening test.
- The low ADAMTS13 level must be documented in your history or confirmed at screening.
- You must be able and willing to follow the study procedures.
- The study team must judge that you can cooperate with study steps and visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a national registry that collects medical information from people diagnosed with a type of blood-clotting disorder called acquired TTP (aTTP). It may help researchers better understand the disease and how it’s managed, without necessarily changing your treatment.
This study collects information from people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during an acute episode. It aims to better understand and improve care for this rare blood disorder.
This trial builds a database to study patterns in blood tests and blood smear findings that can suggest small blood clots in the body. Joining may help researchers learn how to recognize and track these changes over time.
This study looks at how patients with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) are doing while being treated with a replacement therapy called recombinant ADAMTS13. It aims to understand real-world experiences and outcomes.
This study reviews medical records of people with a rare blood clotting disorder called cTTP who received a treatment called rADAMTS13 through an early access program. The goal is to learn more about how the treatment works in real life.
This trial tests whether taking aspirin daily can help prevent the blood-clotting episodes (called TTP) caused by a severe lack of a specific protein in your blood. If you have a history of TTP or a genetic form that increases your risk, this study may help reduce those dangerous episodes.
Hear when a new TTP - Thrombotic Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.